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Prevention of age-related disorders is increasingly in focus of health policies, and it is hoped that 
early intervention on processes of deterioration can promote healthier and longer lives. New 
opportunities to slow down the aging process are emerging with omics fields and precision 
medicine. Data-intensive research has the potential to improve the precision of existing risk factors, 
e.g., to replace coarse-grained markers such as blood cholesterol with more detailed multivariate 
biomarkers. In this paper, we follow an attempt to develop a new aging biomarker. The vision 
among the project consortium, comprising both research and industrial partners, is that the new 
biomarker will be predictive of a range of age-related conditions, which may be preventable 
through personalized nutrition. We combine philosophical analysis and ethnographic fieldwork to 
explore the possibilities and challenges of managing aging through bodily signs that are not 
straightforwardly linked to symptomatic disease. We document how the improvement of 
measurement brings about new conceptual challenges of demarcating healthy and unhealthy states. 
Moreover, we highlight that the reframing of aging as risk has social and ethical implications, as it 
is generative of normative notions of what constitutes successful aging and good citizenship.  
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Scientific technologies are never produced in a cultural or political vacuum (Douglas 2009; Elliot & 
McKaughan 2014), and aging research illustrates well the intertwinement of scientific and political 
problems. Numerous health reports call for better scientific and technological solutions to address 
the socio-economic challenges resulting from population aging in Western societies (OECD 1998; 
European Commission 2018; Sundhedsstyrelsen 2010; WHO 2002; 2015). Science should, 
however, not be viewed solely as a mediator of political ambitions to support longer and more 
active lives. As sociologist Tiago Moreira reminds us, we should also attend to “how science, 
technology and medicine have been themselves implicated in the making of the ageing society” 
(Moreira 2017, p. 7). Science not only offers solutions to a predefined societal problem but also  
contributes to the framing of aging as a health problem. This paper explores the intertwined 
epistemic and social implications of the attempt to prevent disease by measuring and preventing 
aging. Towards this end, we follow an interdisciplinary project within the field of personalized 
nutrition that aims to develop a novel aging biomarker.   
For decades, aging research has explored the potential of promoting healthier and longer 
lives by studying the factors that speed up or slow down the aging process. Aging is typically 
defined as progressive deterioration of body functions over time, and aging is hence associated with 
a higher prevalence of chronic diseases (Sprott 2010). Although aging is unavoidable, the notion of 
healthy aging highlights that the rate of deterioration differs among individuals and is modifiable 
through actions recommended in health policies (WHO 2002; 2015; Lamb 2017; Lassen and 
Moreira 2014). Health policy recommendations are dependent on scientific strategies for measuring 
and monitoring aging, e.g., via molecular signs called aging biomarkers (Butler and Sprott 2000). 
The quest for aging biomarkers has recently intensified with the emergence of omics fields, 
precision medicine, and personalized nutrition, thus opening the possibility of measuring aging 
more precisely through multivariate biomarkers (Levin 2014; Moskalev 2019).1  
We focus in this paper on the recent reconceptualization of aging as risk, which is implied in 
the aforementioned policy reports and in scientific publications highlighting, e.g., how aging is “the 
biggest risk factor for a majority of chronic diseases driving both morbidity and mortality” 
(Kennedy et al. 2014, p. 709). Previous papers in philosophy of science discuss the epistemic and 
 
1 Multivariate biomarkers integrate many variables simultaneously, drawing on datamining strategies and multivariate 
statistics.  
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ethical problems associated with risk profiling and screening of cancer and other complex diseases 
(e.g., Biddle 2016; Green & Vogt 2016; Plutynski 2012; 2017). However, the analysis of the 
specific implications of prevention of age-related disease has so far received less attention in this 
field (see however Blasimme 2017; 2020). Following Blasimme (2020), we contend that the 
“geriatric style of thought”2 brings optimism about the potential of managing later-life pathologies, 
but also faces difficult challenges of scientifically demarcating what counts as healthy and 
unhealthy aging. Moreover, our case study adds to previous scholarship showing how attempts to 
naturalize aging are constitutive of societal norms for managing and disciplining aging bodies (Katz 
1996; Oxlund and Whyte 2014).  
Our analysis combines theoretical philosophical and anthropological analysis and 
ethnographic fieldwork within an ongoing research project aiming to improve strategies to 
counteract sarcopenia, understood as age-related loss of muscle mass. We approach science as 
performative, and look into how data and statistics are practiced, and negotiated in day-to-day 
science writings and settings (Law 2002; Mol 2002). Following the emergence of a new biomarker 
entails unfolding the techniques and forms of knowledge in sociomaterial practices. We aim to do 
so by describing the visions, strategies, and challenges involved in the examined project. The 
empirical material consists of semi-structured qualitative interviews with researchers involved in 
the project and food industry partners, as well as visits to the laboratories. Explicit reference to the 
project name and use of quotations are approved by the involved researchers, but we anonymize 
quotes from interviews used in this paper. 
We begin with an analysis of the potentials and challenges of current research aiming to 
identify aging biomarkers (Section 2) and explore how these challenges play out in practice in the 
research project we have followed (Section 3). Our case illustrates how the identification of aging 
biomarkers not only requires more precise tools for measurement, but also conceptual clarification 
of where to draw the line in a vaguely defined spectrum between health and disease. Finally, we 
discuss how this epistemic problem has social implications for the reconceptualization of aging 





2 Geriatrics, in contrast to gerontology, does not aim at understanding aging per se, but at assessing aging in order to 
improve the management of age-related disease (Gilleard & Higgs 2016). 
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2. Biomarkers to promote healthy aging 
 
A biological marker, or biomarker, is a measurable indicator of health conditions that can inform 
disease diagnosis, treatment, or prevention. Biomarkers are typically defined according to their role 
in guiding medical decision making. Diagnostic biomarkers offer information that supports or 
leaves out some diagnostic possibilities. A simple example is a COVID-19 test for the presence or 
absence of virus RNA or anti-bodies. Predictive biomarkers are typically used to guide selection of 
treatment, as exemplified by tests for genetic variations to guide treatment selection for some types 
of cancer. Finally, prognostic biomarkers aim to predict future health outcomes, as exemplified in 
BRCA-testing for breast cancer. Variants (or biomarkers) that increase disease susceptibility are 
also referred to as risk factors. Aging biomarkers combine elements of all of these features by 
providing new tests that can diagnose age-related conditions or provide a risk profiling of such 
conditions, while also being suggestive of preventive measures to slow down the aging process.  
The concept of aging biomarkers emerged in the literature on gerontology in the 1980s, in 
response to the growing recognition of limitations of using chronological age to predict morbidity 
and lifespan in humans and other species:  
 
A biomarker of aging is a biological parameter of an organism that either alone or in some 
multivariate composite will, in the absence of disease, better predict functional capability at 
some late age than will chronological age (Baker and Sprott 1988, p. 223).  
 
The cited early definition illustrates a central premise for aging research, namely that a “biological” 
or “functional age” can be distinguished from chronological age, where the former reflects an 
evaluation of a person’s physiological and mental health states (see also Nathan, this issue). The 
distinction between functional and chronological age is supported by observations of great variation 
in the speed of decline among individuals within the same (chronological) age group. Differences 
encountered between populations of “fast” and “slow agers” are hoped to point to modifiable 
molecular signs of aging. If biomedical technologies can detect these before a functional decline 
manifests at higher (phenotypic) levels of biological organization, it may be possible to take action 
to age in “healthier” ways.  
 Aging biomarkers are thus intended not only as diagnostic tools for age-related disease but 
also as prognostic tools for health screening. Preventive interventions associated with aging 
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biomarkers include so-called geroprotective drugs and personalized nutrition, that aim to extend the 
general lifespan of an individual by lowering the risk of several age-related diseases (Moskalev 
2019, ed.).3 Blasimme uses the notion of ground-state prevention to highlight how prevention of 
age-related decline aims to boost the baseline vitality as a way to counteract several age-related 
conditions (Blasimme 2020; this issue). But ground-state prevention also reawakens debates on the 
extent to which aging and age-related disease can and should be separated (Sprott 2010), and about 
where to draw the line between the normal and the pathological (Canguilhem 1966/1991; Blasimme 
forthcoming). In his book entitled The Metric Society, macro-sociologist Steffen Mau states: “While 
a diagnosis works on the binary principle of ill versus healthy, health scores are based on scales or 
points. Their purpose is to motivate us not ‘merely’ to be healthy, but to keep striving for 
improvement” (Mau 2019, p. 68). While going beyond the dichotomy between disease and health, 
ground-state prevention raises new question about how to define the spectrum of health states. 
Moreover, it raises the intertwined epistemic and ethical question of whether there is (or should be) 
an upper limit to health improvement. As we shall show, our case illustrates how researchers are 
confronted with these philosophical questions when aiming to develop a new aging biomarker.  
 Biomarker research is currently advanced through technologies that allow for quantitative 
measurement of finer-grained bodily signs. However, the improvement of measurement does not 
automatically lead to improved prognosis or diagnosis. The introduction of the most iconic symbol 
of medicine, the stethoscope, illustrates well the persistent challenge. The invention of the 
stethoscope by Laënnec in 1816 provided a more objective and distanced measurement of what is 
“inside the body” and marked the beginning of technology-driven developments in medicine 
(Reiser 1978). Nevertheless, the extension of human senses also came with new challenges of 
interpretation. While the stethoscope allowed for more precise detection and classification of heart 
murmurs among hospitalized patients, the status of heart murmurs as a diagnostic criterion for heart 
failure remained controversial (Binney 2016). Particularly problematic was the introduction of the 
stethoscope as a vehicle for early diagnosis of heart disease. The Scottish cardiologist James 
Mackenzie criticized how such examinations impacted the lives of individuals with detected heart 
murmurs, as they were advised against doing physical labor and had to pay more for medical 
insurance, before the profession had established any firm knowledge about the relation between 
such signs and symptomatic heart problems (Mackenzie 1919; Binney 2016, p. 89). Since most of 
 
3 For an overview of candidates for human aging biomarkers, see the online database called Digital Aging Atlas 
(http/ageing-map.org, and Craig et al. 2015). 
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these never developed heart problems, the example illustrates how introduction of prognostic 
technologies can unintentionally lead to harm if bodily signs are overinterpreted as indications of 
future disease.4 
We use the example of the stethoscope to illustrate how uncertainty about a diagnostic or 
prognostic test can arise when there is a lack of knowledge about the spectrum of variation of the 
physiological condition measured, or what is sometimes called spectrum bias or spectrum effect 
(Mulherin et al. 2002). Different methodological designs have been explored to overcome this 
problem in biomarker research. A standard procedure in case-control and cohort studies compares 
the prevalence of a candidate risk factor in a patient population versus a healthy control group. The 
need for such methods underscores how biomarkers are inherently comparative and relational. 
They are statistically identified and defined as marking a measurable difference between reference 
populations, rather than representing a fixed biological entity or well-defined causal factor (Russo 
and Vineis 2016). A common approach to identify aging biomarkers is to compare “fast-agers,” 
characterized by a given type of functional deterioration, to “slow agers.” Here, the control group 
represents healthy aging, which can be individuals with above-average health or centenarians as an 
extreme example of “slow aging” (Franceschi and Bonafé 2003; Moreira 2017; Moskalev 2019, 
ed.). Yet, the selection of the relevant reference populations can be challenging in aging research, as 
difficult choices must be taken when determining which individuals are sufficiently healthy to 
represent the control group.5 Moreover, reference values for “normal” aging (functional 
performance or blood metabolites) change over a person’s lifetime, and studies must be designed to 
account for the limitations of comparing and extrapolating test results across age groups.6 
 Biomarkers can be validated by testing their predictive capacity on new populations (or on 
data from similar studies). If successful, the next step is to demonstrate the effects of an 
intervention on the risk factor associated with adverse health outcomes. This is typically attempted 
through randomized controlled trials, comparing the effects of intervening on risk factors in one 
 
4 Similar concerns about the risk of overdiagnosis have been expressed in the historical introduction of other 
technologies of measurement, such as blood pressure measurement, electrocardiography, and X-ray technology 
(Mackenzie 1919, pp.194-195), cancer screening via imaging technologies (Plutynski 2012; 2017), and “big data 
screening” via omics technologies (Green & Vogt. 2016; Vogt et al. 2019). 
5 This challenges is related to what is more generally discussed as the reference class problem, i.e., the problem of how 
the choice of references classes can affect the assignment of probabilities to the individual case (see also Reichenbach 
1949; Hájek 2007). 
6 Estimating how such changes occur over time (and thus how to classify age groups) is particularly challenging as one 
cannot assume that the speed of deterioation changes linearly with chronological age. A recent study suggests that blood 
metabolites change in wave-like dynamics with rapid shifts at certain points in time (Lahallier et al. 2019). Discussing 
the implications of such findings is, however, beyond the scope of this paper.  
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group to a control group. Positive effects are typically most significant where there is a relatively 
simple and strong relationship between risk factor and disease, such as between smoking and lung 
capacity or lung cancer. But it has often proven difficult to change the development of complex 
diseases via interventions on risk factors. For instance, a large randomized controlled study recently 
documented a successful reduction in risk factors of ischemic heart disease (blood cholesterol, 
blood pressure, obesity) through lifestyle intervention. However, after ten years, the researchers 
observed no long-term effect on morbidity and mortality of the intervention group compared to the 
control group (Jørgensen et al. 2014). The challenge of prevention via intervention on classical risk 
factors such as blood cholesterol is also reflected in discussions about the benefit-to-harm ratio of 
statin treatment, especially among individuals with relatively low risk of heart disease (Abrahamson 
et al. 2013; Collins et al. 2016; Dumit 2012; Greene 2007; Ruscica et al. 2018). As we shall see 
below, this challenge is also motivating the project we have followed.  
 A possible explanation for the difficulties of preventing common diseases is that  
traditional biomarkers, such as blood cholesterol, only give a coarse-grained picture of risk that is 
not predictive at the individual level. It is hoped that improvement of measurement, via multivariate 
statistics on large datasets, can better account for interactions between multiple causal factors, thus 
giving way for more precise profiling of aging and risk (Levin 2014; Putin et al., 2016). The aim to 
account for patient-specific differences that impact disease development is pursued in the fields of 
personalized medicine and personalized nutrition. The latter is based on the idea that molecular 
profiling (via blood or stool samples) can help suggest personalized diets of benefit for the 
individual (Scrinis 2015). In the following, we explore how opportunities and challenges play out in 
this field through insights from ethnographic fieldwork in a data-intensive research project that aims 
to develop a rapid and robust screening tool for age-related changes in lipoprotein metabolism. The 
researchers we followed teamed up with a large food industry consortium that wants to explore the 
possibilities of delivering new functional food products for individualized prevention based on 
screening for aging biomarkers. 
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3. The COUNTERSTRIKE project 
 
The COUNTERSTRIKE project will develop a novel analytical methodology for LPD 
determination, sufficiently rapid to allow for nation-wide screening efforts, which facilitate 
early diagnostics of not only sarcopenia, but also metabolic syndrome and related 




3.1. The aim of the COUNTERSTRIKE project  
 
The COUNTERSTRIKE project (COUNTERacting Sarcopenia with proTeins and exeRcise – 
screening the CALM cohort for lIpoprotein biomarKErs) is a collaboration between the University 
of Copenhagen and the University of Amsterdam, along with three industrial partners: Arla Amba 
group, Bruker, and Unilever. It is a highly interdisciplinary project with researchers from 
metabolomics, chemometrics, health statistics, physiology, and medicine. The participating 
researchers and industry partners describe the project as highly exploratory, as an experiment in 
how far it is possible – and desirable - to realize the vision stated in the above quote from the 
project’s webpage.  
The project is focused on developing a valid biomarker of lipoprotein particle distribution 
by creating a protocol for clinical screening based on a comparison of lipoprotein profiles of 
research participants with diet, physiological parameters, physical function, gut microbiome, and 
health perception. Among the methods is a full metabolomic investigation of 3000 biological 
samples collected from healthy persons above the age of 65.8 A key goal is to precisely determine 
the lipoprotein particle distribution (LPD) in blood samples by developing a method that can 
provide rapid and reliable results. Secondly, to link the test results to metabolic measures and 
physiological parameters predictive of age-related deterioration. The project was created as an 
extension of another research project that focused on the prevention of loss of muscle strength 
within the elderly population (called Counteracting Age-related Loss of Skeletal Muscle Mass – 
 
7 Project description at the official homepage of the COUNTERSTRIKE project: 
https://food.ku.dk/english/research_at_food/research-projects/2015/counterstrike-counteracting-sarcopenia-with-
proteins-and-exercise/, accessed Nov 26, 2020.  
 
8 Among the exclusion criteria were health and elderly care dependency, serious chronic diseases, as well as rheumatic 
diseases affecting joints and muscles. For further information on exclusion criteria, see table 1 in (Bechshøft et al. 2016) 
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abbreviated as CALM), and the samples from this study as well as an additional enrollment of 
participants to diversify the sample comprise the COUNTERSTRIKE study cohort.  
The CALM and COUNTERSTRIKE projects are hoped to collect data and develop methods 
that can improve classical biomarkers. A medical doctor, who has been involved in both projects as 
part of his PhD project, expressed the problem with risk profiling via blood cholesterol and blood 
glucose as follows: 
 
I have some concerns about both biomarkers, because we often assume that we understand 
the connections. The concern is justified by the very poor effect of lowering cholesterol 
medically, through statins, on prevention of cardiovascular events, including blood clots. 
[…] You need to treat 138 people to prevent one cardiovascular event. To me, this indicates 
that we haven’t understood the real problem. 
 
A possible explanation for the low effect of the intervention on blood cholesterol relates to the 
many other factors that influence how aging and disease develop in specific individuals. Therefore, 
the researchers hope to improve the predictability of testing procedures through identification of 
multivariate biomarkers (Levin 2014). The researcher in the quote clarified that their project is 
valuable because it offers potential for a complete description of each participant through data from 
questionnaires to macroscopic functional tests and a battery of blood tests. The latter makes 
possible an analysis of the plasma metabolome, the skeletal muscular metabolism, and the plasma 
amino acid profile. The task for the multivariate analysis is then to integrate various types of data to 
provide a more nuanced view of the relation between lipoproteins and age-related diseases. 
Lipoproteins, i.e., macromolecules consisting of fat and protein, are often classified based 
on their tendency to increase the risk of coronary artery disease. For instance, low-density 
lipoprotein (LDL) cholesterol is commonly described as the “bad cholesterol” because it has a 
strong tendency to build up plaques in the arteries, which blocks blood flow, whereas high-density 
lipoprotein (HDL) cholesterol is seen as “good cholesterol” because it can help remove LDL from 
the bloodstream. There are further subclasses, such as intermediate and very-low-density 
lipoproteins (IDL and VLDL), as well as subclasses of each which differ in their molecular 
composition (Monsonis-Centelles et al. 2019). However, a central hypothesis in the 
COUNTERSTRIKE project is that not only the total concentration, but also the relative distribution 
of these and other lipoproteins, matters. As stressed by a co-PI:   
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Instead of just having a single-value biomarker, it's a spectrum of lipoprotein distribution. 
And this is what doctors have shown earlier: you get a different distribution of some of the 
lipoproteins, indicating for example obesity and some cardiovascular diseases. So yes, we 
work holistically, it sounds nice, but multivariate. Doctors have one thing, be it blood 
pressure or cholesterol or glucose levels in the blood, and if it is above some limit, you are 
sick, and if it is below, you are not sick. That doesn't make much sense to us. In all the 
things we investigate, it will rarely look like this. It is typically a multivariate picture, 
because nature is multivariate. 
 
Rather than merely classifying lipoproteins into good or bad types, or interpreting test results 
according to a binary measure of above or below a standard threshold, the hope is that lipoprotein 
distribution profiling (LPD) will provide a more adequate picture of how a person’s health state 
relates to the combinations of several variables. LPD profiles are associated with obesity and insulin 
resistance and may serve as a predictor of cardiovascular risk. In the COUNTERSTRIKE project, 
LPD is further hypothesized to be a more generic aging biomarker that provides a “snapshot of the 
lipid metabolism, making it possible to assess how lipid metabolism differs in health and disease 
states” (Monsonis-Centelles et al. 2019). LPD profiling is in the COUNTERSTRIKE project 
explored as a facilitator of ground-state prevention, by pointing to the need for nutritional changes 
that could delay the onset of several age-related conditions. One of these is sarcopenia, defined as 
age-related loss of skeletal muscle mass, which can result in frequent falls, broken bones, or loss of 
autonomy due to physical disability (Blasimme 2017).9  
In the following, we analyze the key tasks involved in the project and their associated 
challenges. Different tasks were often associated with different disciplines. A large part of the 
project has focused on the development of experimental testing procedures that allow for rapid and 
reproducible measurement of lipoprotein distributions. We describe this task in Section 3.2 as a step 
towards precision measurement. Another task focused on clinical applications and involved the 
collection and modeling of data from an intervention study. Examining this task, we highlight how 
putting precision measurement to use is dependent on the ability to address the theoretical challenge 
of defining a reference scale to represent the spectrum of more or less healthy states. In Sections 
3.3. and 4, we analyze how this persistent challenge of the conceptual demarcation of health forces 
 
9 The specific definition of sarcopenia is currently subject to controversy. We discuss this further in Section 4. 
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stakeholders to reflect on the methodological and theoretical foundations of the experimental 
analyses.  
 
3.2. Towards precision measurement 
 
Any successful biomarker is preconditioned upon precise and reproducible testing procedures. It is 
relatively cheap and fast to measure total cholesterol, LDL, and HDL-cholesterol, as is widely done 
in routine medical health checks. However, the measurement of lipoprotein distribution is much 
more complicated and labor-intensive, as it involves ultracentrifugation procedures to separate the 
different lipoproteins. Therefore, an important aim of the COUNTERSTRIKE project has been to 
develop a faster method relying on nuclear magnetic resonance (NMR) spectroscopy.  
 Deriving information on LPDs from NMR-spectra requires a calibration model that 
establishes a relation between NMR-readings to existing references based on ultracentrifugation. 
An important outcome of COUNTERSTRIKE was to develop such a calibration model and 
demonstrate the reliability and reproducibility of the NMR-based prediction method in a cohort of 
fasting individuals (Monsonis-Centelles et al. 2019). To further establish whether the approach is 
reproducible in different settings, they conducted a so-called “ring test” where collaborators in 
different countries analyzed the same blood sample results in their laboratories for comparison. 
After successfully validating NMR-measurement in the ring test on the same cohort, the next step is 
to validate the method across cohorts and explore the prognostic utility of the multivariate 
biomarker in practice. A co-PI summarizes the status of the project at this point as follows: 
 
We didn’t know much about [the relation between LPD profiling and sarcopenia] when we 
started the project. It was a hypothesis. And what do we know now? We now have the 
method and can use it to see if it works in practice. […] A company that makes NMR-
instruments is very interested in this, because it’s the only way you can make these 
measurements fast, within an hour or half an hour, while an LPD with ultracentrifugation 
will take about a week and involve a lot of work and multiple samples. So there are lots of 
benefits, and that is what we aimed for. The method can be used for other purposes such as 
[tests for] obesity and cardiovascular disease. 
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The researcher further highlighted the importance of showing what he terms “biological replicates” 
instead of mere “replication of measurement.” In other words, the group has to show that the 
calibration method can travel across laboratory contexts and test populations. Commercial 
companies has previously developed such a calibration method. But an important aim in 
COUNTERSTRIKE is to develop openly accessible standard operating procedures that will make 
rapid NMR-based prediction possible as part of routine clinical procedures.  
 However, the strategy of meeting biological complexity through the upscaled complexity of 
measurements is not without challenges. It is generally more challenging to relate markers with 
multidimensional characteristics, such as the LPD and gut microbiome, to clinically relevant 
phenotypic features across cohorts. It is often assumed that increasing the number of variables in a 
risk analysis will automatically provide a more accurate picture of the multiple factors influencing 
disease risk or aging. However, the advantage of access to data on an increasing number of 
variables often comes with an increased risk of overfitting the model. This challenge is also present 
in the COUNTERSTRIKE project, as illustrated in the following quote by a statistical modeler:  
 
[I]f you want to have a biomarker that is really useful, [it should] come up in different 
datasets and in your own. And you should also be quite clever about finding these 
biomarkers, because of what we in the field call overfitting. Maybe you have 100, 200, or 
300 patients, which is a lot, but when you measure so much on these patients, you can 
always find something to discriminate between them.  
 
Researchers often have too much and too little data at the same time. When the number of 
potentially relevant variables and their combinations (the dimensionality) becomes too large, 
compared to the sample size (N), it becomes tremendously challenging to identify the most relevant 
measures. If one compares two population groups to a high number of variables, then it is almost 
always possible to identify statistically significant differences among these groups. The results of 
such a “brute force” method are often not predictable when transferred to other populations, or may 
not be causally relevant for the phenomenon studied.10 This is a general problem for research on 
aging biomarkers, as also expressed in the following by aging researchers Veytsman et al. who 
work on genetic biomarkers:  
 
10 Factors that look statistically predictive often turn out to be causally irrelevant, e.g., when Google Flu Trends 
predicted peaks in flu incidents based on the correlation of flu epidemics and the winter season (Lazer et al. 2014).  
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[T]o generate a reliable biomarker test we need to initially profile many more patients than 
genes… In studies of aging, we essentially predict a “continuous” outcome, as rate of 
descending along the curve of ageing may change non-linearly. This requires either 
enrolling multiple cohorts of individuals, each cohort being within certain age bracket, or 
longitudinal profiling of individuals, with multiple sets of measurements collected long their 
ageing journey. (Veytsman et al. 2019, p. 15) 
 
The quotes illustrate how improvement of measurement technologies is not only dependent on the 
accuracy of testing procedures, but also on how the number of variables relate to the size and 
variation of the reference populations. A strategy used in the COUNTERSTRIKE project to deal 
with this problem was to test the model based on data from the study that had not been used to 
develop the model.11 However, the researchers were confronted with the problem, well known in 
classical epidemiology, that their sample contained too little variation.  
  In the COUNTERSTRIKE project, the study cohort (volunteers above 65 years) turned out 
to be a relatively homogenous cohort of very healthy and fit people. This homogeneity provided a 
challenge for the statistical analysis of the relationship between molecular markers and physical 
deterioration, and for the effects of the intervention study itself. A positive effect on the increase in 
muscle mass and overall health was expected to be established in the intervention group via training 
and dietary changes. However, the intervention group’s sub-cohort were all above 83 and were 
already relatively healthy (some of them revealed themselves as former marathon runners during 
the intervention). As a result, they observed no statistically significant differences between the 
intervention group and a control group that did not undergo training intervention (Bechshøft et al. 
2017). The homogeneity of the cohort also presented a problem for the validation of the NMR 
model, as clarified by a co-PI in the project:  
      
Unfortunately, our cohort consists of old people with little variation in age. And it turns out 
that they are relatively healthy. […] When we develop methods, we would like to be able to 
include extremes. In part to see if [the relation] is linear, and if the findings fit in the model. 
And we haven’t gained that.  
 
 
11 Another important strategy to deal with overfitting is feature selection, i.e., select for those known to be biologically 
relevant or to remove variables that are only weakly correlated with the age. This can for instance be done through a 
statistical procedure called Principal Component Analysis.  
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The researchers had hoped to use their developed NMR model to define a health spectrum, 
corresponding to a scale of health scores discussed previously, but the cohort only allowed them to 
map a small spectrum of possible health states. We shall return to this point in Section 4. First, we 
document how the aim of measuring aging often led to discussions about how to conceptually 
distinguish between healthy and unhealthy states.  
 
3.3. Measuring aging and (re)defining health  
 
An essential vision for the COUNTERSTRIKE project is to develop a so-called health landscape. A 
health landscape, or “health space,” is a concept increasingly used in metabolomics and preventive 
systems medicine (Levin 2014). Disease development or aging are represented as trajectories from 
healthy to unhealthy states (understood as compositions of some parameters). Possible interventions 
and their effects can be represented as vectors that can alter the speed or direction of an aging 
trajectory. In the context of the COUNTERSTRIKE project, the health landscape offers a 
conceptual framework for understanding LPD profiles as points in a multidimensional state space, 
and the development of these as trajectories of healthy or unhealthy aging. As clarified by a 
statistical modeler in COUNTERSTRIKE: 
 
The meaningful connection should be described not as causal but as correlative. The task is 
not to identify an entity or pattern, but more like drawing the map of a health-landscape, in 
order to establish the relationship between lipoprotein distribution and phenotype. 
 
In other words, rather than aiming to identify specific causal factors, the LPD profile and other 
measures are envisioned to provide information about how the co-occurrence and distribution of 
multiple factors contribute to the health status of an individual, via a statistical correlation between 
LPD values and phenotypic measures. This perspective aligns with reasoning styles in systems 
biology, where focus is shifted from the identification of specific disease-related causes or 
mechanisms to an exploration of the spectrum of factors that influence dynamic states, from 
resilience to deterioration (Sholl & Rattan 2019; see also Sholl this issue). Some areas in the 
statistically defined landscape are envisioned to be associated with increased risk of disease, and 
aging can accordingly be viewed as a trajectory towards diseased states that may be counteracted 
through interventions that push the system into a healthier state or trajectory.  
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The vision of a health landscape thus entails a view of aging processes as modifiable, 
similar to how reports on aging by WHO often feature a functional capacity model showing 
possible outcomes on intervention on aging trajectories (WHO 2002; Lassen and Moreira 2014). 
However, health landscapes in personalized nutrition differ from general functional capacity models 
by aiming to account for more individualized factors. In the context of COUNTERSTRIKE, the 
interventions are envisioned to be recommendations that target a personal profile developed from 
finer-grained measures, such as LPD profiling or gut microbiome sequencing. In the words of a co-
PI: 
It’s down to the personal level – what is good for you, and what is not good for you. And it 
may be that the good nutrition for you is bad for others. If we can, in a relatively simple 
way, via a blood test or a stool sample, measure something that adequately predicts your 
response to nutrition, or a physical activity intervention, then we would be much closer to be 
able to help some. Or help the right people at least, and we could give much more targeted 
diet recommendations, for instance, that would actually work.  
 
The co-PI further pointed out that many general dietary recommendations lack proper evidence of 
benefits, and personalized nutrition is hoped to change this situation. Making health landscapes 
actionable for personalized disease prevention is, however, still a vision to be realized. It requires 
that it is possible to draw boundaries around what should count as more or less healthy states or 
trajectories, i.e., it requires a scale on which health scores can be related to phenotypic measures. As 
seen above, this task was complicated by the homogeneity of the COUNTERSTRIKE cohort. The 
more fundamental problem is that such scales may be defined in multiple ways, depending on the 
disciplinary perspective and the means of measurement. 
At project meetings between academic collaborators and industry partners, Hillersdal 
observed how the researchers struggled to find a useful health definition for this purpose. While 
industry partners were asking for test results that allow them to develop and market protein products 
to specific LPD-profiles, statisticians expressed difficulties in delivering quantitative results without 
prior agreement on what health is. In one of the meetings, a statistician drew a circle in a coordinate 
system (Figure 1) to represent the requirement of boundaries that quantitatively demarcate data 
points representing healthy and unhealthy states. Pointing to the circle representing such a 
boundary, he said: “Define health for me, and I will find it for you,” To that, a metabolomics 
industry partner replied: “No, give me a pattern, and I will give you health!” 
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Figure 1. A reconstruction of the 
illustration drawn by the statistician in a 
meeting to illustrate the need to draw 
boundaries between healthy and unhealthy 




The discussion raises interesting questions about who has the capacity and right to define health, 
and in which scientific field this conceptual demarcation should be made. While the statistician 
expects the health sciences to provide the starting criteria for his analysis, the metabolomics 
industry partner’s response illustrates a common expectation that a quantitative definition of health 
will emerge from a statistical analysis. However, the statistician insists that his analysis cannot get 
off the ground without a predefined clinical notion of health that he can label the data-populations 
according to. 
 The challenges experienced in the COUNTERSTRIKE project is reminiscent of broader 
discussions in personalized medicine, where pioneers such as Leroy Hood have called for the 
development of wellness landscapes to allow for diagnosis through a comparision of “the 
expression level of a sample of molecules in a specimen from the individual with a health-
associated reference expression region of the sample of molecules” (Hood and Siegal 2011, §2, our 
emphasis). However, as documented in an analysis by Vogt, Hoffman, and Getz (2016a), 
identifying a “reference expression” presupposes a health reference population that cannot itself be 
identified via data-intensive methods. Hence, the requirement for a reference population, makes the 
effort of biomarker precision inherently dependent on preexisting notions of health that the same 
field is trying to update and go beyond. The circularity in the task to improve definitions of health 
or aging need not be vicious, as ongoing scientific analyses can iteratively improve existing 
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biomarkers and sharpen medical definitions (cf. Chang 2004). But it illustrates how translation of 
precision measurements into prognostic tools requires critical reflection on what is measured.   
The difficulty of defining healthy aging was in the COUNTERSTRIKE project further 
complicated by disciplinary differences, as highlighted in the following quote by a statistician:  
 
Well, I think that [the disciplines] have a very different views on what health actually is, and 
how we actually… With these tools, are we measuring health? Or what aspects of health are 
we measuring? To what extent are we measuring which aspects of health, and how are they 
connected? This is super interesting in connection to methodologies, because what has NMR 
to do with health? What has big data got to do with health? 
 
Following their discussions, Hillersdal observed how the researchers struggled to find a way to 
integrate various disciplinary perspectives in a joint measurement of healthy aging. Similar 
challenges of interdisciplinary integration have been reported in the literature (Green and Andersen 
2019; MacLeod 2018; Nersessian 2017), including the difficulty of translating dynamic notions of 
health and disease into quantitative measures (Levin 2014). The challenge to evaluate the utility of 
the multivariate biomarker is particularly hard when the targets of intervention are not symptomatic 
people but healthy elderly citizens. Instead of labeling data populations according to clinically 
validated disease categories, and evaluating effects of intervention according to hard endpoints such 
as morbidity, the points of comparison are here degrees of health and risk. The challenge to 
document short-term effects of personalized risk analysis and dietary changes is illustrated in an 
interview with a metabolomics industry partner:  
 
[T]hese data are not good enough to really say, this product will reduce your cardiovascular 
risk, but can it say, for example that it reduces LDL cholesterol, and this may be related to a 
reduced risk. So, it helps to understand the health benefits of our products. And if we 
understand the mechanisms of actions, we can also find ingredients which target these 
mechanisms of actions, and then we have much more control on what our products do to the 
metabolism. 
 
While the quote signals optimism for future benefits, it also highlights how the vision may still be 
in the distant future. The industry partners further envisioned that supermarkets would begin to 
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cater to the individual consumer and offer specific functional foods suitable for their phenotype. 
However, the quote also underscores how the relation between risk factor and disease risk remains 
uncertain, and it is generally difficult to document the health benefits of nutritional changes that are 
solid enough to market (Scrinis 2015). The critical challenge for the food industry is to get evidence 
that documents the health benefits among a group of individuals who are already relatively healthy. 
In her own words:  
 
[It] is very difficult to show beneficial effects. We have put a lot of money to demonstrate 
that for our ingredients, but humans are so diverse, and we are not a pharmaceutical 
company, so we don’t look at diseased people. We look at healthy people. And how do you 
then say that somebody becomes healthier? How do we define that? That is very difficult. 
  
Reframing the task of biomarkers, from a reduction in morbidity or specific disease risk to make the 
healthy healthier, raises interesting questions about the scope of personalized nutrition and 
management of aging bodies in general. It also illustrates how the quest for aging biomarkers 
presupposes and potentially coproduces norms of what constitutes healthy aging. The quotes seem 
to suggest that any aging trajectory, no matter how slow it may be, could become a potential target 
for further risk reduction. Hence, research on aging biomarkers brings new light to discussions 
about how risk management is historically constructed through a complex interplay of epistemic 
and non-epistemic values (Douglas 2009: Hilgartner 1992). But whereas scholarship on 
medicalization has focused on the role of pharmaceutical companies (Dumit 2012; Greene 2007; 
Oxlund and Whyte 2014), personalized nutrition exemplifies how investments from the food 
industry also take part in the shaping of health concepts. 
 
4. Aging as risk 
 
Section 3 described the difficulties of developing a scale or health landscape to compare LPD test 
results to. A researcher involved in COUNTERSTRIKE commented on this challenge by 
emphasizing that the identification of a biomarker for sarcopenia requires a study design that 
divides population groups into different degrees of sarcopenia. He referred to the expression that “it 
is not physiology, but world records, that define how far man can jump”. This saying highlights 
how biomarker research needs a material referent of (extreme) variation to get off the ground. The 
researcher’s critical reflection on the limitations of their study design resonates with George 
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Canguilhem’s criticism of Auguste Comte, who insisted that the normal and its “true limits of 
variation” could and should be defined before investigating pathological cases (Canguilhem 
1966/1996, p. 53). In contrast, Canguilhem argued that the normal is always defined in relation to 
the pathological, and that neither are free of normative connotations. The discussion on sarcopenia 
illustrates this point well, as it is not clear where an age-related loss of muscle mass falls on the 
spectrum between the normal and the pathological.  
Aging involves a gradual loss of muscle mass, but at what point does sarcopenia become a 
risk factor or a health issue that calls for intervention? Sarcopenia was introduced in 1989 as a 
medical term for age-related loss of muscle mass, but, in 2016, it was assigned a disease code in the 
International Classification of Disease (ICD-10) system (Bülow et al. 2019). Bülow et al. 
problematize the new consensus definition because it conflates loss of skeletal muscle mass with 
loss of physical function. Aside from the risk of making the definition tautological or circular, the 
definition conceals that loss of physical function can have many other causes. Moreover, loss of 
physical function is a complex measure that is not straightforwardly related to health problems, 
which raises ethical dilemmas. As Blasimme (2017) highlights, if sarcopenia is defined as 
functional decline, and hence as a potential reduction in a person’s freedom to maintain autonomy 
in daily life, then the health care system would be ethically committed to doing something about it 
(e.g., to implement a screening and treatment program). On the other hand, if a person could have 
an age-related loss of muscle mass without suffering from functional decline, the medicalization of 
sarcopenia becomes more controversial. Hence, debates on sarcopenia illustrate how scientific 
categories and social values are intertwined and may mutually constrain each other (Longino 2002; 
Plutynski 2012; 2017).  
 A recurring theme observed in the project meetings and interviews with participants in the 
COUNTERSTRIKE project was the question of what happens when the health system increasingly 
treats risk (e.g., hypertension or sarcopenia), and not only symptomatic disease. If specific profiles 
of lipoprotein distributions can be shown to be associated with sarcopenia, what is then measured 
by a test for the risk of sarcopenia? Are we testing for a risk factor of a disease? Or a risk factor of a 
risk factor? Some participants expressed concerns about the increasing focus on risk factors, about 
where to draw the line, and whether the benefits of interventions outweigh the potential harms and 
costs of medical testing. One researcher viewed the future visions for disease prevention as 
completely unrealistic, as what he described as a “prediction-risk-screening-mania”:  
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[I]n my view, loss of muscle mass is not a pathological phenomenon, but a symptom. […] 
It’s this whole idea of treating risk factors… As I said earlier, a disease is ontologically 
different from a risk factor. A disease is manifest, it exists at the present point in time. It has 
an ontology, whereas the risk factor, it doesn’t exist as such.  
 
The quote nicely illustrates the awareness that risk categories are plastic and highly dependent on 
how we draw the lines between health and risk. Since medically or socially constructed kinds can 
become reinforced through scientific programs (Hacking 1995), the intensified focus on risk factors 
potentially entails an extension of conditions that need to be treated (see also Greene 2007; Dumit 
2012). As illustrated in the example with the stethoscope and measurement of heart murmurs, it is 
difficult to evaluate the clinical significance of the loss of muscle mass or altered metabolism. As 
expressed by a statistician in the COUNTERSTRIKE project:  
 
What are we measuring? Aging is not a disease, and it has not been proven that a 20-year-
old always has a better metabolism.  
 
The quote indicates a concern that the reframing of aging as risk may promote a vision of aging 
itself as a disease. Moreover, since the focus is shifted from intervening on symptomatic disease to 
improving metabolic conditions, the potential becomes open-ended. As Blasimme (forthcoming) 
points out, ground-state prevention does not necessarily confine itself to a process of normalization 
of the unhealthy. It can also be seen as a way of enhancing human capacities more generally, 
through the attempt to control and postpone aging. 
It could be argued that reconceptualizing aging as risk is relatively harmless, as long as 
screening for aging biomarkers is primarily used to evaluate the need for lifestyle changes, such as 
recommendations for exercise or personalized diet. Such arguments have been advanced in the 
context of precision medicine, where proponents distinguish their strategies for health promotion 
from traditional screening (Magis et al. 2018). However, the negative impact of medicalization is 
not necessarily tied to increased medication. Instead, medicalization refers to the implications of 
defining more and more aspects of life in relation to aims defined within the medical domain 
(Conrad 2007; Vogt et al. 2016b). If there is no upper limit to what constitutes healthy aging, any 
sign of deterioration becomes a potential target for age-preventive strategies (Estes and Binney 
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1989; Oxford and Whyte 2014). As a result, attempts to slow down the aging process may become a 
life-long preoccupation, or what Blasimme (2020) calls the agificication of life itself.  
In the context of personalized medicine and personalized nutrition, concerns also relate to 
the increasing organization of health care around individualized risk (Green and Vogt 2016; Hogle 
2019). While the notions of active or healthy aging come with new possibilities for “disciplining 
aging,” they also involve increasing responsibilization of individuals and potential stigmatization of 
“passive” lifestyles as a failure to age successfully (Katz 1996; Katz and Marshall 2003; Lassen 
2014; Lassen and Jespersen 2017). In other words, the emphasis on healthy aging and public health 
policies implies an imperative to implement strategies towards this aim. As a researcher in the 
COUNTERSTRIKE project problematized:  
 
It again returns to the question of sarcopenia. Before we have even figured out what it is, we 
are supposed to move on to how we can make things better. But what does “better” mean? 
Isn’t that something that the individual in a free, liberal society has to decide for himself? To 
decide what is good or bad for him, as long as it doesn’t hurt anyone else?  
  
The researcher here points to how the aim to avoid sarcopenia is not self-evident, as it is unclear to 
what extent sarcopenia presents a health problem, and for whom. The quote highlights how an ideal 
of healthy aging always promotes certain norms of socially and clinically acceptable forms of living 
and aging. By pointing to physiological problems and possible interventions to solve these, 
prevention programs implicitly assume that staying healthy is the most important priority. In 
practice, however, the norms that underlie health programs sometimes clash with the situated values 
of elderly individuals (Wareham 2018).  
An ethnographic study associated with the CALM project documented how several project 
participants viewed the active aging policies in the European Union as an intrusion on how they 
should live their lives (Lassen and Jespersen 2017). Several participants viewed chronic diseases 
and functional decline as a natural part of life, of growing older, and not as something that 
necessarily calls for preventive action. As the researchers highlight: 
 
While active aging provides the answer that independence and activity are good for all, it 
does not answer what happens to those who cannot live up to the expectations of an active 
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and healthy old age, and who might envision other ways of aging well. (Lassen and 
Jespersen 2017, p. 153) 
 
Alternative visions of aging well can also be observed among the resourceful. Even individuals who 
were very active, i.e., well above average for their age group, criticized the health policies as part of 
a “health regime” taken too far. They joked about how drinking schnapps and playing billiard were 
part of what they understood as “active aging” and that they had earned a right to live as they 
please. Similarly, Hillersdal observed in a focus group interview with elderly research participants 
in COUNTERSTRIKE how the suggestion of protein supplements to help prevent sarcopenia 
conflicted with their concept of healthy food. These observations resonate with another Danish 
study documenting how users of blood pressure meters and glucometers expressed resistance 
towards the idea of always being reminded of potential risks and responsibilities to control these 
(Andersen and Whyte 2014; Oxlund and Whyte 2014). Such observations should caution against 
overenthusiasm about the effects of techniques that can “yield data independent of the opinions and 
appearance of the patient” (Reiser 1978, p. 43). For healthy aging strategies to have the intended 
effect, they have to align with the target audience’s values. 
The norms of healthy or active aging in health policies may be prone to what philosopher 
Nancy Jecker calls midlife bias, i.e., the tendency to assume that values important to individuals at 
mid-life also transfer to older age (Jecker 2020; this issue).12 Health policies may presuppose that 
values such as independence, physical activity, and autonomy are good for all and of equal 
importance at all times. Jecker highlights the extreme example of how we often try to respect 
autonomy long after it is beyond the capacities of a person with severe dementia (see also Gjødsbøl 
et al. 2017). Similarly, it is important to keep in mind that preventing sarcopenia to maintain 
physical functionality may not always be the primary goal, as it has to compete with other values of 
a good life, such as freedom from dietary restrictions or stigmatization of lifestyle choices. From the 
perspective of elderly citizens, it may also be relevant to consider how maintenance of autonomy, 
e.g., capacity to perform daily tasks despite sarcopenia, can often be achieved in other ways, such as 
via the use of assistive devices (Blasimme 2017). Our aim is not to problematize current health 
 
12 Similarly, Wareham (this issue) questions the the objectivity of midlife valuations of life at old age, considering both 
the aim to live longer and hoping to die before experiencing harms of aging.   
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policies per se, but rather to expose the normative assumptions in the discourse on individualized 
strategies for healthy aging and open these for further scrutiny.13   
Interestingly, these deep philosophical problems were also present in meetings in the 
COUNTERSTRIKE project. In one meeting, one of the researchers asked, “why don’t we talk 
about the good death?” The open question was posed as a reaction to the focus on the physiological 
aging body as something that needs to be shaped and intervened on, thus excluding vulnerability 
and decay as natural processes of old bodies (cf. Kaufman 2015). It highlights how the very notions 
of “aging biomarkers,” “healthy aging,” and “active aging” are simultaneously scientific concepts 
and policy tools that influence the very way aging is viewed and enacted (Lassen and Moreira 2014; 





Advanced technologies of measurement and big data analysis are opening new venues for 
population-wide screening-efforts to determine disease risk and potential individual actions on 
entire age-segments. This paper has described an attempt to develop a multivariate aging biomarker, 
understood as a sign of functional deterioration that leads to increased risk of sarcopenia and other 
age-related conditions. The approach exemplifies what Blasimme (this issue) calls ground-state 
prevention, which aims to delay the onset of several life-limiting pathologies. In this case, the 
researchers developed a data-intensive tool for precise measurement of lipoprotein distribution. 
However, they were confronted with difficulties in interpreting the measures without a stable 
referent for what counts as healthy and unhealthy states.   
It has been exciting to follow how the challenges encountered in the exploratory 
COUNTERSTRIKE project led participants to critically reflect on their own project’s implicit 
assumptions. Participants raised concerns about the potential increase in the medicalization of 
aging, which may follow the intensified focus on risk factors, to which their own project also 
contributes. However, the fieldwork also documented a joint commitment to reduce 
 
13 Similarly, Sholl and Rattan (2019) emphasize that the most effective strategies to promote healthy aging may be to 
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overmedicalization through imprecise testing. In this sense, precision measurement points to the 
potential of risk-stratified strategies in response to growing insights into how people age differently. 
We find that the development of the COUNTERSTRIKE project exemplifies an unusual space for 
scientific exploration, philosophical reflection, and at times expression of different viewpoints 
among the different participants. These aspects of scientific practices are not visible in scientific 
publications but can be documented through ethnographic fieldwork.  
The COUNTERSTRIKE project illustrates how epistemic and ethical issues intersect when 
health policies and scientific efforts increasingly focus on “risk reduction”. The intensified focus on 
prevention of aging let us believe that we can “grow older without aging” (Katz and Marshall 
2003), by providing possibilities of action to counteract the aging process. Yet, as this ideal seems 
achievable only to a limited extent, it raises the question of what it means to age “healthy” or 
“naturally,” whether there is an upper limit to healthy aging, and how such limits are shaped by 
science policy. The intensified focus on aging biomarkers and the management of age-related 
disease raise intriguing questions about the implications of medicalization and agification of life 
itself, and about what the promotion of better and longer lives entails. While science can inform us 
about the relations between phenotypic functions and resilience to perturbations, we cannot escape 
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